Immix Biopharma, Inc.

Immix Biopharma, Inc. (IMMX) priced its initial public offering on Dec 17, 2021 at $5.00 per share, within its $5.00–$6.00 range, raising $21M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $65.9M. ThinkEquity was lead-left underwriter. Sheppard Mullin advised the company and Dorsey & Whitney advised the underwriters.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a class of Tissue-Specific Therapeutics for oncology and inflammation. Its lead asset, IMX-110, is in Phase 1b/2a trials for solid tumors in the United States and Australia.

Status

IPO

Ticker

IMMX

Exchange

Nasdaq Capital Market

Priced

Dec 17, 2021

IPO price

$5.00

Price range

$5.00–$6.00

Raised

$21M

Market cap at IPO price

$65.9M

First filed

Sep 17, 2021

Underwriters

ThinkEquity

Company counsel

Sheppard Mullin

Underwriters' counsel

Dorsey & Whitney

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.